Effects of policosanol 20 versus 40 mg/day in the treatment of patients with type II hypercholesterolemia: a 6-month double-blind study.
Quick navigation
Link to full study
http://www.ncbi.nlm.nih.gov/pubmed/11708574
Conclusion of this study
In conclusion, although the tolerability profile remains excellent, according to the present results policosanol at a dose of 40 mg/day does not offer significant additional cholesterol-lowering efficacy over the 20 mg/day dose.
Supplements analyzed in this study
|
Health conditions analyzed in this study
No health conditions information for this study.Functions related to this study
|
||
|
Body systems related to this study
 Cardiovascular System |